# NT5C2

Source: https://onco.cc/targets/nt5c2/  
OnCo record `nt5c2` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

NT5C2 (Cytosolic purine 5'-nucleotidase) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Non-Hodgkin lymphoma, Breast cancer and 1 more.

## Summary

Broad specificity cytosolic 5'-nucleotidase that catalyses the dephosphorylation of 6-hydroxypurine nucleoside 5'-monophosphates. In addition, possesses a phosphotransferase activity by which it can transfer a phosphate from a donor nucleoside monophosphate to an acceptor nucleoside, preferably inosine, deoxyinosine and guanosine. Has the highest activities for IMP and GMP followed by dIMP, dGMP and XMP.

CIViC holds 18 clinical evidence items and 0 assertions across 6 variants, naming Mercaptopurine, Thioguanine, Nelarabine and Arabinosylguanine and others. Open Targets scores its association with cancer at 0.61 (direct and indirect evidence; datatypes literature 0.75, genetic association 0.00, somatic mutation 0.97).

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: 5'-nucleotidase, cytosolic II; Cytosolic purine 5'-nucleotidase; PNT5; cN-II; SPG65; NT5B; SPG45
- Tags: cancer-genes-wave
- Symbol: NT5C2
- Class: enzyme
- Biology: Broad specificity cytosolic 5'-nucleotidase that catalyses the dephosphorylation of 6-hydroxypurine nucleoside 5'-monophosphates. In addition, possesses a phosphotransferase activity by which it can transfer a phosphate from a donor nucleoside monophosphate to an acceptor nucleoside, preferably inosine, deoxyinosine and guanosine. Has the highest activities for IMP and GMP followed by dIMP, dGMP and XMP. Could also catalyse the transfer of phosphates from pyrimidine monophosphates but with lower efficiency. Through these activities regulates the purine nucleoside/nucleotide pools within the cell. Location: Cytoplasm, cytosol (UniProt). Locus 10q24.32-q24.33 (HGNC).
- Where found: Leukaemia: Open Targets association 0.55 with leukaemia (MONDO_0005059); Non-Hodgkin lymphoma: Open Targets association 0.55 with non-Hodgkin lymphoma (MONDO_0018908); Breast cancer: Open Targets association 0.50 with breast cancer (MONDO_0007254); Acute lymphoblastic leukaemia: Open Targets association 0.53 with acute lymphoblastic leukaemia (MONDO_0004967); CIViC evidence names this disease

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 8 therapies; CIViC holds 18 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Childhood Acute Lymphocytic Leukaemia; T-cell Acute Lymphoblastic Leukaemia.

## Sources

- HGNC HGNC:8022: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8022
- UniProt P49902: https://www.uniprot.org/uniprotkb/P49902/entry
- NCBI Gene 22978: https://www.ncbi.nlm.nih.gov/gene/22978
- Ensembl ENSG00000076685: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000076685

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)

---
JSON: https://onco.cc/api/v1/entities/nt5c2.json